Testosterone recovery after stopping ADT – who is at risk for long-term non-recovery? Presented by Pierre Blanchard, MD Gustave Roussy. #APCCC24 Written coverage by Zach Klaassen Georgia Cancer Center MCG Urology. > bit.ly/4aVAN1S Advanced Prostate Cancer Consensus Conference

Hot flushes – how can we help our patients? Presented by ONCODOC St. Vincent's University Hospital. #APCCC24 Written coverage by Zach Klaassen Georgia Cancer Center MCG Urology. > bit.ly/3y3YC97 Advanced Prostate Cancer Consensus Conference

Radical prostatectomy is good option in selected high risk and locally advanced (T3) PCA patients. #SPCG15 RCT study will give more data. Role of eLND under discussion. PSMA-PET sensitivity and specificity still not optimal. #APCCC24

Many thanks and congratulations to silke gillessen and aurelius omlin and the superb #APCCC24 team on another spectacularly successful meeting! A clear consensus (unanimously) a great success 😀

Great session and great panel to discuss the ⁦The Lancet⁩ Prostate Cancer Commission. Many thanks to #APCCC24 for featuring prominently. Will be a fantastic launch pad for new initiatives. ⁦The ICR⁩ thelancet.com/pdfs/journals/…

💫🌟  #APCCC24 Day 3️⃣ Highlights 🌟💫
Advanced Prostate Cancer Consensus Conference OncoAlert
silke gillessen aurelius omlin
1. 🧬 Dr. Heather Cheng - Urgency of germline testing in advanced prostate cancer. Detecting mutations to open up personalized treatment options. 🔬 #GeneticsInCancer

2. 🌐 Dr. Ana Aparicio -…

Gynecomastia – how to assess and treat? Presented by Prof Lisa Horvath, MBBS, PhD, University of Sydney. #APCCC24 Written coverage by Rashid K. Sayyid University of Toronto. > bit.ly/3UlmeO4 Advanced Prostate Cancer Consensus Conference.

#APCCC2024 Advanced Prostate Cancer Consensus Conference 👉 Pierre Blanchard, MD ‘s excellent talk on serum testosterone suppression after limited ADT and testosterone recovery 👉implications on QOL, & testosterone replacement Rx👇OncoAlert Oncology Brothers UroToday.com PCF Science Courtney Bugler

Advanced Prostate Cancer Consensus Conference 2024 Consesnsus!

High-risk locally advanced Pc Neha Vapiwala silke gillessen
🔸What is the ideal definition?
🔸DRE vs MRI for T stage
🔸Lymph node staging what is standard?
🔸Genomic classifiers & AI as predictors of tx benefit

Happy Mexican panelist 👩🏻‍⚕️🇲🇽🦀

We are happy to share our current manuscript: In an exploratory post-hoc analysis of IMmotion151 (mRCC, atezo + beva) and IMvigor211 (mUC, atezo), in which we correlated baseline electrolyte concentration with ICB response and outcome in an unbiased manner, we made an interesting…

The importance of bone protection. Presented by Noel W. Clarke, MD, The Christie and Salford Royal Hospitals. #APCCC24 Written coverage by Zach Klaassen Georgia Cancer Center MCG Urology. > bit.ly/3UDo12g Advanced Prostate Cancer Consensus Conference

How to select ADT and an ARPI based on cardiovascular risk profile. Presented by Charles Ryan University of Minnesota. #APCCC24 Written coverage by Zach Klaassen Georgia Cancer Center MCG Urology. > bit.ly/44fCWmN Advanced Prostate Cancer Consensus Conference

#ARAMON trial: Darolutamide monotherapy and testosterone levels in biochemically recurrent #ProstateCancer . Andy Laccetti MD, MS Memorial Sloan Kettering Cancer Center and Zach Klaassen Georgia Cancer Center discuss in this conversation on UroToday > bit.ly/3W56VM6

Debate: how to best manage a fit patient with high-risk localised and locally advanced #prostatecancer ? Presented by Jason Efstathiou, MD, DPhil, Harvard Medical School. #APCCC24 Written coverage by Rashid K. Sayyid University of Toronto. > bit.ly/3y6wIJC Advanced Prostate Cancer Consensus Conference.

Genetic overlap discovered between cancerous and non-cancerous bladder tissue in small study. Roger Li Moffitt Cancer Center joins Sam S. Chang MD, MBA Vanderbilt Urology to discuss genetic profiles in #NMIBC and adjacent benign bladder tissue > bit.ly/3UvRiMC

Broadening treatment horizons with CDK4/6 inhibitors from breast to #ProstateCancer . Rana McKay UC San Diego joins Alicia Morgans, MD, MPH Dana-Farber as part of an independent medical education initiative supported by Loxo@Lilly Oncology Medical > bit.ly/40KPX5Y

How to deal with the projected rise of #prostatecancer cases in the Chinese healthcare system. Presented by Dingwei Ye, Fudan University. #APCCC24 Written coverage by Zach Klaassen Georgia Cancer Center MCG Urology. > bit.ly/3UyOle6 Advanced Prostate Cancer Consensus Conference

How to identify aggressive variant prostate cancer? Presented by Himisha Beltran, MD, Dana-Farber Harvard Medical School. #APCCC24 Written coverage by Rashid K. Sayyid Univ of Toronto Urology IHPME. > bit.ly/4duXufl Advanced Prostate Cancer Consensus Conference

Dealing with inequality – the promise and pitfalls for social media and AI for prostate cancer in disadvantaged populations. Presented by Stacy Loeb, MD New York University. #APCCC24 Written by Zach Klaassen Georgia Cancer Center MCG Urology. > bit.ly/3JGeGAJ Advanced Prostate Cancer Consensus Conference

How to utilize presence or absence of CT findings on a PSMA PET/CT? Presented by prof. Stefano Fanti IRCCS Azienda Ospedaliero-Universitaria di Bologna. #APCCC24 Written coverage by Zach Klaassen Georgia Cancer Center MCG Urology. > bit.ly/3JDb8PK Advanced Prostate Cancer Consensus Conference